Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clopidogrel injunction retained

Executive Summary

A preliminary injunction halting sales of generic Plavix by Apotex has been upheld by Washington, D.C. Federal Appeals Court, Sanofi-Aventis and Bristol-Myers Squibb announce Dec. 8. The ruling affirms the Aug. 31 decision by the U.S. District Court for the Southern District of New York granting Sanofi/Bristol's motion for a preliminary injunction enjoining Apotex from infringing Sanofi's patent by selling generic clopidogrel (1"The Pink Sheet" Sept. 4, 2006, p. 3). Sanofi/Bristol filed the motion for preliminary injunction Aug. 15 in response to Apotex' Aug. 8 "at risk" launch. Apotex said it is considering further review of the lower court decision. The trial on the underlying patent infringement dispute is scheduled to begin Jan. 22...

You may also be interested in...

Plavix Generic Blocked By Court, But Damage Lingers For Bristol And Sanofi

The impact of the launch of a generic version of Plavix - the second best selling drug in the world - will continue to weigh on Sanofi-Aventis and Bristol-Myers Squibb at least through the remainder of the year and possibly beyond despite a ruling in their favor barring Apotex' sale of generic clopidogrel

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Balancing Act: China Approves Antiviral For Coronavirus While Promoting Traditional Medicines

Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts